- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive Officer, will present at the 8th Annual Needham Life Sciences Conference on Thursday, June 11, 2009 at 11:00 am ET at the New York Palace Hotel in New York City. Dr. Lewis will provide an overview of the Company and its clinical development programs.
To access the live audio webcast, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for ninety days.
About ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer drugs. The Company is currently focused on three clinical programs.
Palifosfamide (ZymafosTM or ZIO-201) references a novel composition (tris formulation) that is the functional active metabolite of ifosfamide, a standard of care for treating sarcoma, lymphoma, testicular, breast and other cancers. Palifosfamide delivers only the cancer fighting component of ifosfamide. It is expected to overcome the resistance of ifosfamide and cyclophosphamide in certain cancers. It does not have the toxic metabolites of ifosfamide that cause the debilitating side effects of “fuzzy brain” (encephalopathy) and severe bladder inflammation. Intravenous palifosfamide is currently in a randomized Phase II trial to treat unresectable or metastatic soft tissue sarcoma in the front- and second-line setting, a study expected to establish the basis for a registration trial as early as the first half of 2010. An oral form of palifosfamide has been developed preclinically to the investigational new drug application stage.
Indibulin (ZybulinTM or ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and cancer cell migration. Indibulin is expected to have several potential benefits, including oral dosing for global patient reach, application in multi-drug resistant tumors, no neuropathy and minimal overall toxicity. Indibulin has shown early activity in Phase I study as a single agent in many types of solid tumors and in combination with oral capecitabine (Xeloda®) in a Phase IB trial. Oral indibulin preclinical “dose density” and “metronomic” dose administration studies with our partner and consultant Dr. Larry Norton have progressed to the point of translation with the intention of further pursuit in Phase I/II study in a subset of breast cancer patients to be performed under the direction of Drs. Clifford Hudis and Jose Baselga. A nanoparticle formulation (for oral and IV forms) is in preclinical evaluation.
Darinaparsin (ZinaparTM or ZIO-101) is a novel mitochondrial-targeted agent (organic arsenic) being developed for the treatment of various hematologic and solid cancers. Preclinical and Phase I and II results to date demonstrate that darinaparsin is much less toxic than other forms of arsenic and without the cardiotoxicty of inorganic arsenic. Intravenous darinaparsin is completing a Phase II hematology trial with initial results of strongly positive treatment activity, and absence of side effects in lymphoma that could form the basis, following dialogue with regulatory authorities, for a registration trial. Phase I study with the oral form continues with maximum tolerated dose not yet reached.
ZIOPHARM’s operations are located in Boston, MA with an executive office in New York.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates, risks related to the sufficiency of existing capital reserves to fund continued operations for a particular amount of time and uncertainties regarding the Company’s ability to obtain additional financing to support its operations thereafter. The Company assumes no obligation to update these forward-looking statements, except as required by law.
For more information, please click here
ZIOPHARM Oncology, Inc.
International Investor Relations Inc.
Copyright © Business Wire 2009If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Brightness-equalized quantum dots improve biological imaging October 5th, 2015
Sniffing out cancer with improved 'electronic nose' sensors October 2nd, 2015
Hopes of improved brain implants October 1st, 2015
Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC(TM) Delivery System: Data to be presented September 27 at the European Cancer Conference 2015 in Vienna September 11th, 2015